CMRA (Comera Life Sciences Holdings) Research & Development: $1.44 Mil (TTM As of Sep. 2023)


What is Comera Life Sciences Holdings Research & Development?

Comera Life Sciences Holdings CMRA Research & Development is $1.44 Mil as of Sep. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Comera Life Sciences Holdings's Research & Development for the three months ended in Sep. 2023 was $0.37 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was $1.44 Mil.

Comera Life Sciences Holdings  (OTCPK:CMRA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Comera Life Sciences Holdings Research & Development Related Terms

Comera Life Sciences Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings Research & Development Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Research & Development
1.26 1.75 1.74

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.40 0.49 0.34 0.24 0.37

Comera Life Sciences Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.44 Mil mean?
Comera Life Sciences Holdings (CMRA) has a Research & Development of $1.44 Mil as of Sep. 2023. Research and development expense is the total cost for research and development activities. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' Research & Development too high?
Comera Life Sciences Holdings' current Research & Development is $1.44 Mil.
How does Comera Life Sciences Holdings' Research & Development compare to FREQ and BNTC?
Comera Life Sciences Holdings' Research & Development of $1.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current Research & Development is $1.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current Research & Development of $1.44 Mil. The current Research & Development is $1.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current Research & Development is $1.44 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.